Cited by 1,155Multiple Myeloma Research and TreatmentsBone health and treatmentsMultiple Sclerosis Research Studies

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Open access

Attal, Michel, Lauwers-Cances, Valerie, Marit, Gerald, Caillot, Denis, Moreau, Philippe, Facon, Thierry, Stoppa, Anne Marie, Hulin, Cyrille, Benboubker, Lofti, Garderet, Laurent, Decaux, Olivier, Leyvraz, Serge, Vekemans, Marie-Christiane, Voillat, Laurent, Michallet, Mauricette, Pegourie, Brigitte, Dumontet, Charles, Roussel, Murielle, Leleu, Xavier, Mathiot, Claire, Payen, Catherine, Avet-Loiseau, Hervé, Harousseau, Jean-Luc·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1114138

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: High-dose chemotherapy with autologous stem-cell transplantation is a standard treatment for young patients with multiple myeloma. Residual disease is almost always present after transplantation and is responsible for relapse. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide maintenance therapy after transplantation. METHODS: We randomly assigned 614 patients younger than 65 years of age who had nonprogressive disease after first-line transplantation to maintenance treatment with either lenalidomide (10 mg per day for the first 3 months, increased to 15 mg if tolerated) or placebo until relapse. The primary end point was progression-free survival. RESULTS: Lenalidomide maintenance therapy improved median progression-free survival (41 months, vs. 23 months with placebo; hazard ratio, 0.50; P<0.001). This benefit was observed across all patient subgroups, including those based on the β(2)-microglobulin level, cytogenetic profile, and response after transplantation. With a median follow-up period of 45 months, more than 70% of patients in both groups were alive at 4 years. The rates of grade 3 or 4 peripheral neuropathy were similar in the two groups. The incidence of second primary cancers was 3.1 per 100 patient-years in the lenalidomide group versus 1.2 per 100 patient-years in the placebo group (P=0.002). Median event-free survival (with events that included second primary cancers) was significantly improved with lenalidomide (40 months, vs. 23 months with placebo; P<0.001). CONCLUSIONS: Lenalidomide maintenance after transplantation significantly prolonged progression-free and event-free survival among patients with multiple myeloma. Four years after randomization, overall survival was similar in the two study groups. (Funded by the Programme Hospitalier de Recherche Clinique and others; ClinicalTrials.gov number, NCT00430365.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1114138

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citation
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Self-citation
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
A PROSPECTIVE, RANDOMIZED TRIAL OF AUTOLOGOUS BONE MARROW TRANSPLANTATION AND CHEMOTHERAPY IN MULTIPLE MYELOMA
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citation
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Self-citation

Flagged first, then by citations

Show all 24 references

Sorted by citations

Items 501–600 of 1,000

Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry
Rifkin, R. M., Jagannath, S., Durie, B. G. M., Narang, M., Terebelo, H. R., Gasparetto, C., TOOMEY, K. E., Hardin, J. W., Wagner, L. I., Parikh, K., et al. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.05.017 · Cited by 14
Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
Beaussant, Y., Daguindau, É., Pugin, A., Mohty, M., Avet‐Loiseau, H., Roos‐Weil, D., Michallet, M., Chevalier, P., Raus, N., Cheikh, J. E., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.04.020 · Cited by 14
Self-citation
Maintenance therapy for multiple myeloma in the era of novel agents
Facon, T. T. F. (2015) · Hematology · doi:10.1182/asheducation-2015.1.279 · Cited by 14
Self-citation
Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis
Suzuki, K., Sunami, K., Ohashi, K., Iida, S., Mori, T., Handa, H., Matsue, K., Miyoshi, M., Bleickardt, E. W., Matsumoto, M., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.18 · Cited by 14
Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors
Ghosh, A., Politikos, I., & Perales, M. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000408 · Cited by 14
Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against
Richardson, P. G. G., Holstein, S. A., Schlossman, R. L., Anderson, K. C., Attal, M., & McCarthy, P. L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1409207 · Cited by 14
Self-citation
Minimal residual disease and log‐reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma
Rossi, G., Falcone, A. P., Minervini, M. M., Cillis, G. P. D., de Waure, C., Sisti, L. G., Giambra, V., Valente, D., Chiello, V., Scalzulli, P. R., et al. (2018) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21755 · Cited by 14
Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma
Patel, D. A., Gopalakrishnan, R., Engelhardt, B. G., McArthur, E., Sengsayadeth, S. M., Culos, K., Byrne, M. T., Goodman, S. A., Savani, B. N., Chinratanalab, W., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0791-y · Cited by 14
Clinical treatment of newly diagnosed multiple myeloma
Cejalvo, M. J., & de la Rubia, J. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1078236 · Cited by 14
Patient with Refractory Multiple Myeloma Developing Eosinophilia after Lenalidomide Treatment and Lung Cancer 9 Months Later: Case Report and Review of the Literature
Sekiguchi, Y., Shimada, A., Imai, H., Wakabayashi, M., Sugimoto, K., Nakamura, N., Sawada, T., Komatsu, N., & Noguchi, M. (2014) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-014-0355-7 · Cited by 14
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency*
Ogunniyi, A., Rodríguez, M., Devlin, S. M., Adel, N. G., Landau, H. J., Chung, D. J., Lendvai, N. K., Lesokhin, A. M., Koehne, G., Mailankody, S., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1239261 · Cited by 14
Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN)
Brioli, A., Manz, K. M., Pfirrmann, M., Hänel, M., Schwarzer, A. C., Prange‐Krex, G., Fabisch, C., Knop, S. T., Illmer, T., Krammer‐Steiner, B., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03101-z · Cited by 14
A T-cell–based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy
Bruins, W. S. C., Smits, F., Duetz, C., Groen, K., Korst, C. L. B. M., de Jonge, A. V., Verkleij, C. P. M., Rentenaar, R., Cosovic, M., Eken, M., et al. (2025) · Blood · doi:10.1182/blood.2025028587 · Cited by 13
Self-citation
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study
Chang, J. E., Havighurst, T. C., Kim, K., Eickhoff, J. C., Traynor, A. M., Kirby‐Slimp, R., Volk, L. M., Werndli, J. E., Go, R. S., Weiss, M., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13957 · Cited by 13
Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant
Karam, D., Gertz, M. A., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., Dingli, D., Buadi, F. K., Kapoor, P., Kourelis, T., Warsame, R. M., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01631-8 · Cited by 13
Part I: The Role of Maintenance Therapy in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
McCarthy, P. L. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0006 · Cited by 13
Lenalidomide and second malignancies in myeloma patients
Pratt, G. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70001-4 · Cited by 13
Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations
Matarraz, S., Paiva, B., Díez‐Campelo, M., Bárrena, S., Jara‐Acevedo, M., Gutiérrez, M. L., Sayagués, J. M., Sánchez, M.-L., Bárcena, P., Garrastazul‐Sánchez, M. P., et al. (2014) · Leukemia · doi:10.1038/leu.2014.103 · Cited by 13
Maintenance and continuous therapy for multiple myeloma
Richardson, P. G. G., Laubach, J. P., Gandolfi, S., Facon, T. T. F., Weisel, K. C., & O’Gorman, P. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1490181 · Cited by 13
Self-citation
Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
Byun, J. M., Lee, J., Shin, S.-J., Kang, M., Yoon, S., & Koh, Y. (2018) · Blood Research · doi:10.5045/br.2018.53.2.105 · Cited by 13
Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation
For the Fukuoka Blood and Marrow Transplantation Group, Yamasaki, S., Yoshimoto, G., Kohno, K., Henzan, H., Aoki, T., Tanimoto, K., Sugio, Y., Muta, T., Kamimura, T., et al. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2538-8 · Cited by 13
Multidisciplinary Professional Roles Addressing Needs in Multiple Myeloma: An Innovative ‘Virtual’ Pharmacist Surveillance Clinic
Ebied, M., & Chan, V. (2021) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2021.151173 · Cited by 13
Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
Al‐Mansour, Z., & Ramanathan, M. (2014) · Advances in Hematology · doi:10.1155/2014/652395 · Cited by 13
Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work
Bashir, Q., & Qazilbash, M. H. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0374-1 · Cited by 13
Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma
Koomen, D. C., Meads, M. B., Magaletti, D. M., Guingab-Cagmat, J. D., Oliveira, P. S., Fang, B., Liu, M., Welsh, E. A., Meke, L. E., Jiang, Z., et al. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00022 · Cited by 13
Have drug combinations supplanted stem cell transplantation in myeloma?
Palumbo, A. P., & Cavallo, F. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.335.3792205 · Cited by 13
Lenalidomide: A Review of Its Continuous Use in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Stem-Cell Transplantation
McCormack, P. L. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0269-6 · Cited by 13
Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy
Phipps, C., Linenberger, M. L., Holmberg, L., Green, D., Becker, P. S., Connelly‐Smith, L. S., Klippel, Z. K., Burwick, N. R., Gopal, A. K., Bensinger, W., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.13 · Cited by 13
Identifying Professional Education Gaps and Barriers in Multiple Myeloma Patient Care: Findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee
Raje, N. S., Faiman, B. M., Harvey, R. D., Kurtin, S. E., Lonial, S., Kumar, S. K., Cohen, A. D., Conde, M. Á., Giralt, S., Recine, M. S., et al. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.04.011 · Cited by 13
The use of Novel Agents in Multiple Myeloma Patients with Hepatic Impairment
Stansfield, L., Gonsalves, W. I., & Buadi, F. K. (2015) · Future Oncology · doi:10.2217/fon.14.270 · Cited by 13
Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the M yeloma F oundation of A ustralia M edical and S cientific A dvisory G roup
Quach, H., Joshua, D. E., Ho, J., Szer, J., Spencer, A. G., Harrison, S. J., Mollee, P. N., Roberts, A. W., Horvath, N., Talulikar, D., et al. (2015) · Internal Medicine Journal · doi:10.1111/imj.12640 · Cited by 13
The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma
Mel, S. D., Chen, Y., Gopalakrishnan, S., Ooi, M. G. M., Teo, C., Tan, D., Teo, M., Tso, A. C. Y., Lee, L. Y. K., Nagarajan, C., et al. (2016) · Singapore Medical Journal · doi:10.11622/smedj.2016150 · Cited by 14
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response
Mina, R., Petrucci, M. T., Corradini, P., Spada, S., Patriarca, F. F., Cerrato, C., Paoli, L. D., Pescosta, N., Ria, R., Malfitano, A., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.05.019 · Cited by 14
Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database
Handa, H., Ishida, T., Ozaki, S., Mori, A., Kato, K., & Iida, S. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283931 · Cited by 12
Impact of bortezomib‐based versus lenalidomide maintenance therapy on outcomes of patients with high‐risk multiple myeloma
Bumma, N., Dhakal, B., Fraser, R. A., Estrada‐Merly, N., Anderson, K. C., Freytes, C. O., Hildebrandt, G. C., Holmberg, L., Krem, M. M., Lee, C., et al. (2023) · Cancer · doi:10.1002/cncr.34778 · Cited by 13
Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation
Kawamura, K., Takamatsu, H., Ikeda, T., Komatsu, T., Aotsuka, N., Amano, I., Yamamoto, G., Watanabe, K., Ohno, Y., Matsue, K., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.02.015 · Cited by 12
Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents
Nathwani, N., Larsen, J. T., & Kapoor, P. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0310-9 · Cited by 12
Impact of lenalidomide‐based induction therapy on the mobilization of CD34+ cells, blood graft cellular composition, and post‐transplant recovery in myeloma patients: a prospective multicenter study
Partanen, A., Valtola, J., Silvennoinen, R. H., Ropponen, A., Siitonen, T., Putkonen, M., Sankelo, M., Pelkonen, J., Mäntymaa, P., Varmavuo, V., et al. (2017) · Transfusion · doi:10.1111/trf.14220 · Cited by 13
Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time.
Kazandjian, D. G., & Landgren, O. (2019) · PubMed · Cited by 12
Post-Transplant Maintenance Treatment Options in Multiple Myeloma
Karam, D., & Kumar, S. K. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00143-7 · Cited by 12
Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma
Marneni, N., & Chakraborty, R. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00631-7 · Cited by 12
Comparative study of therapy‐related and de novo adult b‐cell acute lymphoblastic leukaemia
Rahman, Z. H. A., Parrondo, R. D., Heckman, M. G., Wieczorek, M. A., Miller, K. C., Alkhateeb, H. B., Sproat, L. Z., Murthy, H. S., Hogan, W. J., Kharfan‐Dabaja, M. A., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17906 · Cited by 12
Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands
Brink, M., Minnema, M. C., Visser, O. J., Levin, M., Posthuma, E. F. M., Broijl, A., Sonneveld, P., van der Klift, M., Roeloffzen, W. W. H., Westerman, M., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00640-6 · Cited by 12
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma
Parrondo, R. D., Rahman, Z. A., Heckman, M. G., Wieczorek, M. A., Jiang, L., Alkhateeb, H. B., Litzow, M. R., Greipp, P. T., Sher, T., Bergsagel, P. L., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00680-y · Cited by 12
Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma
Pasvolsky, O., Milton, D. R., Rauf, M., Tanner, M. R., Bashir, Q., Srour, S. A., Tang, G., Saini, N. Y., Ramdial, J., Masood, A., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.07.028 · Cited by 12
Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma
Chen, L., & Gooding, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1038329 · Cited by 13
The impact of social vulnerability index on survival following autologous stem cell transplant for multiple myeloma
Salafian, K., Mazimba, C., Volodin, L., Varadarajan, I., Pilehvari, A., You, W., Knio, Z. O., & Ballen, K. K. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02200-x · Cited by 12
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment
Zago, M., Oehrlein, K., Rendl, C., Hahn‐Ast, C., Kanz, L., & Weisel, K. C. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2149-2 · Cited by 12
Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
Fouquet, G., Hébraud, B., Garciaz, S., Stoppa, A. M., Roussel, M., Caillot, D., Chrétien, M. L., Arnulf, B., Szalat, R. E., Garderet, L., et al. (2014) · Journal of Cancer · doi:10.7150/jca.8541 · Cited by 12
Self-citation
Standardisation of minimal residual disease in multiple myeloma
Innao, V., Allegra, A., Russo, S., Gerace, D. G., Vaddinelli, D., Alonci, A., Allegra, A. G., & Musolino, C. (2017) · European Journal of Cancer Care · doi:10.1111/ecc.12732 · Cited by 12
Moving Toward Continuous Therapy in Multiple Myeloma
Bonello, F., Cetani, G., Bertamini, L., Gay, F., & Larocca, A. (2019) · Clinical Hematology International · doi:10.2991/chi.d.191101.001 · Cited by 13
Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study
Arora, M., Chen, Y., Hageman, L., Wu, J., Landier, W., Francisco, L., Kung, M., Ness, E., Bosworth, A., Pamukçuoğlu, M., et al. (2020) · Cancer · doi:10.1002/cncr.32941 · Cited by 14
Phase II trial of single‐agent panobinostat consolidation improves responses after sub‐optimal transplant outcomes in multiple myeloma
Mithraprabhu, S., Kalff, A., Gartlan, K. H., Savvidou, I., Khong, T. T., Ramachandran, M., Cooke, R. E., Bowen, K. M., Hill, G. R., Reynolds, J., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.17080 · Cited by 12
History and Development of Autologous Stem Cell Transplantation for Acute Myeloid Leukemia
Gorin, N. C. (2021) · Clinical Hematology International · doi:10.2991/chi.k.210703.002 · Cited by 12
Nonselective proteasome inhibitors in multiple myeloma and future perspectives
Gavriatopoulou, M., Malandrakis, P., Ntanasis‐Stathopoulos, I., & Dimopoulos, M. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1999411 · Cited by 13
Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches
Szalat, R. E., & Munshi, N. C. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159017 · Cited by 12
Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy
Krishnan, A. Y., Vij, R., Keller, J., Dhakal, B., & Hari, P. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159016 · Cited by 12
U nited K ingdom M yeloma F orum ( UKMF ) position statement on the use of bendamustine in myeloma
Pratt, G., Bowcock, S. J., Lai, M., Bell, S., Bird, J. M., D’Sa, S., Cavenagh, J. D., Cook, G., Morgan, G. J., Owen, R. G., et al. (2013) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12097 · Cited by 12
Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of A ustralia M edical and S cientific A dvisory G roup
Quach, H., Joshua, D., Ho, J., Szer, J., Spencer, A. G., Harrison, S. J., Mollee, P. N., Roberts, A. W., Horvath, N., Talaulikar, D., et al. (2015) · Internal Medicine Journal · doi:10.1111/imj.12688 · Cited by 12
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide
Rollison, D. E. M., Komrokji, R. S., Lee, J., Hampras, S. S., Fulp, W. J., Fisher, K. J., Baz, R., Nishihori, T., Xu, Q., Olesnyckyj, M., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1207763 · Cited by 12
Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions
Jung, S., Koh, Y., Kim, M. K., Kim, J. S., Moon, J., Min, C., Yoon, D. H., Yoon, S. S., Lee, J., Hong, C. M., et al. (2025) · Blood Research · doi:10.1007/s44313-025-00055-9 · Cited by 11
Current Approaches to the Initial Treatment of Symptomatic Multiple Myeloma
Jasielec, J. K., & Jakubowiak, A. J. (2013) · International Journal of Hematologic Oncology · doi:10.2217/ijh.13.3 · Cited by 12
Smoldering multiple myeloma – Past, present, and future
Mann, H., Katiyar, V., Varga, C., & Comenzo, R. L. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100869 · Cited by 12
Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma
Patel, K. K., Shah, J. J., Feng, L., Lee, H. C., Manasanch, E. M., Olsem, J. B., Morphey, A. N., Huo, X. J., Thomas, S. K., Bashir, Q., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3420 · Cited by 11
MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort
Vià, M. D., Lionetti, M., Marella, A., Matera, A., Travaglino, E., Signaroldi, E., Galbussera, A. A., Lucca, U., Mandelli, S., Riva, E., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006498 · Cited by 11
Single‐agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience
Pasvolsky, O., Milton, D. R., Masood, A., Sami, S. S., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., Lin, P. Y., Ramdial, J., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27029 · Cited by 11
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine, and Total Body Irradiation Conditioning Is Effective in an Elderly and Infirm Population
Brammer, J. E., Stentz, A., Gajewski, J., Curtin, P. T., Hayes‐Lattin, B., Kovacsovics, T. J., Leis, J. F., Meyers, G., Nemecek, E. R., Subbiah, N., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.09.024 · Cited by 11
Myeloma Propagating Cells, Drug Resistance and Relapse
Karadimitris, A., Chaidos, A., Caputo, V. S., Goudevenou, K., Ponnusamy, K., & Xiao, X. (2015) · Stem Cells · doi:10.1002/stem.2199 · Cited by 11
Pomalidomide Desensitization in a Patient Hypersensitive to Immunomodulating Agents
Seki, J. T., Sakurai, N., Lam, W., & Reece, D. E. (2017) · Current Oncology · doi:10.3747/co.24.3572 · Cited by 11
Combined Use of Ninjin'yoeito Improves Subjective Fatigue Caused by Lenalidomide in Patients With Multiple Myeloma: A Retrospective Study
Ito, T., Konishi, A., Tsubokura, Y., Azuma, Y., Hotta, M., Yoshimura, H., Nakanishi, T., Fujita, S., Nakaya, A., Satake, A., et al. (2018) · Frontiers in Nutrition · doi:10.3389/fnut.2018.00072 · Cited by 11
Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond
Kocoglu, M. H., & Badros, A. Z. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1756258 · Cited by 11
A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma
Richard, S., Jagannath, S., Cho, H. J., Parekh, S. S., Madduri, D., Richter, J. R., & Chari, A. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2021.1858790 · Cited by 11
Continuous treatment with new agents for newly diagnosed multiple myeloma
Zou, Y., Sheng, Z., Lu, H., & Yu, J. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32836032d5 · Cited by 11
Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma
Škerget, M., Skopec, B., Žontar, D., & Černelč, P. (2016) · Radiology and Oncology · doi:10.1515/raon-2016-0028 · Cited by 11
Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma
Noonan, K. A., & Colson, K. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.05.005 · Cited by 12
Predictive Factors for Early Relapse in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplant
Pourmoussa, A., Spielberger, R. T., Cai, J., Khoshbin, O., Farol, L. T., Cao, T. M., & Sahebi, F. (2019) · The Permanente Journal · doi:10.7812/tpp/19.012 · Cited by 11
Response Improvement Rather than Response Status after First Autologous Stem Cell Transplantation Is a Significant Prognostic Factor for Survival Benefit from Tandem Compared with Single Transplantation in Multiple Myeloma Patients
Blocka, J., Hielscher, T., Goldschmidt, H., & Hillengaß, J. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.03.006 · Cited by 11
The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT
Hwang, A., Hayden, P. J., Pawlyn, C., McLornan, D. P., & Garderet, L. (2024) · British Journal of Haematology · doi:10.1111/bjh.19353 · Cited by 10
Self-citation
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Grieb, N., Oeser, A., Ferle, M., Hanke, F., Flossdorf, S., Sauer, S., Goldschmidt, H., Müller‐Tidow, C., Salwender, H.-J., Fenk, R. R., et al. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02490-1 · Cited by 10
The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma
Joks, M., Jurczyszyn, A. J., Machaczka, M., Skotnicki, A. B., & Komarnicki, M. A. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12412 · Cited by 11
Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?
Barosi, G., & Gale, R. P. (2019) · Leukemia · doi:10.1038/s41375-019-0383-2 · Cited by 10
Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis
Bonello, F., Pulini, S., Ballanti, S., Gentile, M., Spada, S., Annibali, O., Omedè, P., Ronconi, S., Cangialosi, C., Podda, L., et al. (2019) · Cancers · doi:10.3390/cancers11111735 · Cited by 11
Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment
Groot, C. A. U., Ramsden, R., Lee, D., Boersma, J., Zweegman, S., & Dhanasiri, S. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13497 · Cited by 10
Therapy-related myeloid neoplasms following treatment for multiple myeloma—a single center analysis
Boquoi, A., Banahan, S. M., Mohring, A., Savickaite, I., Strapatsas, J., Hildebrandt, B., Kobbe, G., Gattermann, N., Haas, R. R., Schroeder, T. A., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04775-1 · Cited by 10
The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease
Richardson, P. G. G., Mateos, M., Vangsted, A. J., Ramasamy, K., Abildgaard, N., Ho, P. J., Quach, H., & Bahlis, N. J. (2022) · Expert Review of Proteomics · doi:10.1080/14789450.2022.2142564 · Cited by 11
Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience
Pasvolsky, O., Gaballa, M., Milton, D. R., Masood, A., Sami, S. S., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., Ramdial, J., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.01.010 · Cited by 10
Mature results of MM‐011: A phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma
Lazaryan, A., Hussein, M. A., Reu, F. J., Faiman, B. M., Habecker, B., Karam, M. A., Reed, J., Hamilton, K. M., Waksman, J. A., Bruening, K., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23639 · Cited by 10
Current Treatment Strategies with Lenalidomide in Multiple Myeloma and Future Perspectives
Larocca, A., Cavallo, F., Mina, R., Boccadoro, M., & Palumbo, A. P. (2012) · Future Oncology · doi:10.2217/fon.12.124 · Cited by 10
From evidence to clinical practice in blood and marrow transplantation
Khera, N. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.04.001 · Cited by 10
Role of Consolidation Therapy in Transplant Eligible Multiple Myeloma Patients
Cavo, M., Brioli, A., Tacchetti, P., Zannetti, B. A., Mancuso, K., & Zamagni, E. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.07.001 · Cited by 10
The Shreveport Myeloma Experience: Survival, Risk Factors and Other Malignancies in the Age of Stem Cell Transplantation
Munker, R., Shi, R., Nair, B. S., Devarakonda, S. S., Cotelingam, J. D., McLarty, J. W., Mills, G. M., & Glass, J. (2015) · Acta Haematologica · doi:10.1159/000440970 · Cited by 10
Is it possible to cure myeloma without allogeneic transplantation?
Katodritou, E., Papadaki, S., Konstantinidou, P., & Terpos, E. (2016) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2016.01.015 · Cited by 10
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial
Parrish, C., Morris, C., Williams, C. D., Cairns, D. A., Cavenagh, J. D., Snowden, J. A., Ashcroft, J., Cavet, J., Hunter, H. M., Bird, J. M., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.01.016 · Cited by 10
Concomitant MDS with isolated 5q deletion and MGUS : case report and review of molecular aspects
Nolte, F., Mossner, M., Jann, J.-C., Nowak, D., Boch, T., Müller, N., Hofmann, W., & Metzgeroth, G. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12827 · Cited by 10
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma
Mark, T. M., Guarneri, D., Forsberg, P. A., Rossi, A., Pearse, R. N., Perry, A., Pekle, K. A., Tegnestam, L., Greenberg, J., Shore, T. B., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.03.007 · Cited by 10
Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis
Thoennissen, G. B., Görlich, D., Bacher, U., Aufenberg, T., Hüsken, A.-C., Hansmeier, A., Evers, G., Mikesch, J., Fritz, F., Bokemeyer, C., et al. (2017) · Acta Haematologica · doi:10.1159/000463534 · Cited by 10
Chart Review Across EU5 in MM Post-ASCT Patients
Ashcroft, J., Judge, D., Dhanasiri, S., Taylor‐Stokes, G., & Middleton‐Dalby, C. (2018) · International Journal of Hematologic Oncology · doi:10.2217/ijh-2018-0004 · Cited by 10
The immunomodulatory-drug, lenalidomide, sustains and enhances interferon-α production by human plasmacytoid dendritic cells
Kibata, K., Ito, T., Inaba, M., Tanaka, A., Iwata, R., Inagaki‐Katashiba, N., Phan, V. T. X., Satake, A., & Nomura, S. (2019) · Journal of Blood Medicine · doi:10.2147/jbm.s206459 · Cited by 10
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma
Stroh, J., Seckinger, A., Heider, M., Rudelius, M., Eichner, R., Schick, M., Slawska, J., Emde, M., Salwender, H. J., Bertsch, U., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005532 · Cited by 10
Lenalidomide induced secondary Acute Lymphoblastic Leukemia in a Multiple Myeloma patient: A case-report
Khan, S. R., Tariq, M., Fayyaz, S. M., Soomar, S. M., & Moosajee, M. (2022) · Leukemia Research Reports · doi:10.1016/j.lrr.2022.100315 · Cited by 10

Authors: Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., Decaux, O., Leyvraz, S., Vekemans, M.-C., Voillat, L., Michallet, M., Pegourie, B., Dumontet, C., Roussel, M., Leleu, X., Mathiot, C., Payen, C., Avet-Loiseau, H., & Harousseau, J.-L.
Affiliations: Hôpital Purpan (FR)
CHU Dijon Bourgogne (FR)
Hôpital Claude Huriez (FR)
Institut Paoli-Calmettes (FR)
Centre Hospitalier Régional et Universitaire de Nancy (FR)
Hôpital Saint-Antoine (FR)
Hôpital Pontchaillou (FR)
Centre Hospitalier Universitaire Vaudois (CH)
Centre Hospitalier Universitaire de Besançon (FR)
Hôpital Edouard Herriot (FR)
Institut Curie (FR)
ORCID: Attal, Michel
Caillot, Denis
Moreau, Philippe
Facon, Thierry
Hulin, Cyrille
Garderet, Laurent
Decaux, Olivier
Leyvraz, Serge
Vekemans, Marie-Christiane
Michallet, Mauricette
Dumontet, Charles
Roussel, Murielle
Leleu, Xavier
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-05-10
Volume: 366
Issue: 19
Pages: 1782-1791
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1114138
OpenAlex: W2128084036
Semantic Scholar: c28c0ef900dcfd0347dbf26ecd97d5547f948a9a
Cited by: 1,155
References: 24
Citations by year: 2026: 32 · 2025: 36 · 2024: 43 · 2023: 61 · 2022: 70 · 2021: 85 · 2020: 79 · 2019: 68 · 2018: 83 · 2017: 98 · 2016: 108 · 2015: 86 · 2014: 102 · 2013: 133 · 2012: 68
FWCI: 82.78
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Digital Access to Libraries (submittedVersion)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
IRIS (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Keywords: lenalidomide, maintenance therapy, multiple myeloma, autologous stem cell transplantation, progression-free survival, event-free survival, secondary malignancies, peripheral neuropathy, young patients, residual disease
MeSH terms: Lenalidomide, Adult, Aged, Antineoplastic Agents, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma, Thalidomide, Neoplasms, Second Primary, Disease-Free Survival, Stem Cell Transplantation, Kaplan-Meier Estimate, Young Adult, Maintenance Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks